Dr. Nataliya Karyakina brings extensive expertise in toxicology and risk assessment to RSI. With a Ph.D. in Toxicology and experience at the McLaughlin Centre for Population Health Risk Assessment, she specializes in evaluating health risks from exposure to various toxic agents. Her research spans essential and toxic metals, pharmaceuticals, and nanomaterials. She has contributed to projects on chemical classification and labeling, as well as health-based regulatory guidance. Currently, she focuses on the health effects of engineered nanoalumina and diagnostic criteria for occupational manganism.

Now serving as RSI's Vice-President Communications and Strategic Initiatives, for years Cemil has provided organizations with guidance designed to transmit mission-critical messages. An anti-tobacco campaign is not about promoting a strategy, it's about saving...

Daniel Krewski began his career in the federal government of Canada, focusing on programs within Health Canada, particularly in food safety and environmental health. Trained in mathematics, statistics, and biostatistics, his multidisciplinary background reflects the complex nature of risk science. He later transitioned to academia, founding the McLaughlin Centre for Population Health Risk Assessment at the University of Ottawa. There, he developed new methodologies and collaborated internationally. In 2006, he co-founded Risk Sciences International, aiming to provide expert advice on diverse risk issues. His contributions have been instrumental in shaping risk assessment frameworks used by organizations like Health Canada and the U.S. Environmental Protection Agency. In 2023, Dr. Krewski passed the CEO's baton to Greg Paoli; he remains active as RSI Chief Risk Scientist.

Rosanna Wong holds a B.Sc. in Environmental Science from the University of Waterloo, with diverse co-op experiences ranging from aquaculture research in the Netherlands to botany collections in Canada. She transitioned into risk analysis, initially as a Junior Analyst at Risk Sciences International, focusing on food safety and public health. Currently, she conducts research on food safety, transportation, and climate change, and leads the development of a climate resilience tool that integrates both qualitative and quantitative data.

With a B.Math, M.Sc, and Ph.D in Statistics from Carleton University, Shintaro Hagiwara specialized in optimal design for quantitative high-throughput screening and a value-of-information framework for regulatory decision-making. He honed his communication skills through teaching and consulting roles at Carleton. Since joining Risk Sciences International in 2023, his focus has been on applying the VOI framework and developing health-based guideline values for chemicals.

Greg Paoli earned both his Bachelor's and Master's degrees from the University of Waterloo, specializing in engineering and systems design. His early career involved diverse research projects at the University of Waterloo's Institute for Risk Research. Greg later founded Decisionalysis Risk Consultants in 1997 and co-founded Risk Sciences International in 2006. He has served on multiple high-profile committees, including those under the U.S. National Academy of Sciences. As CEO of Risk Sciences International, Greg focuses on risk-based regulatory transformations and has developed enabling technologies like FDA-iRISK. His work spans various sectors, from food and chemical safety to public health, and he continues to contribute to the advancement of risk-based decision-making methodologies.

Natalia Shilnikova earned her medical degree and a PhD in Medical Sciences, focusing on epidemiology related to nuclear facilities. She moved to Canada in 2007, joining the University of Ottawa McLaughlin Centre for Population Health Risk Assessment. Since joining Risk Sciences International in 2011, Dr. Shilnikova has worked on projects involving toxicology, epidemiology, and human health risk assessment, including systematic reviews and toxicity profiles for various chemicals and drugs. She has also contributed to post-approval surveillance of novel cancer drugs.

Franco Momoli transitioned from animal sciences to become an epidemiologist and biostatistician. Initially intrigued by human aging and Alzheimer's Disease, he later focused on cancer etiology and innovative statistical methods. As a professor at the University of Ottawa, he mentored graduate students and led multinational studies. He also worked at research institutes in Ottawa, contributing to diverse clinical research. Currently, he is the Practice Lead for Chemical and Product Safety at Risk Sciences International and an adjunct professor. His work spans from assessing environmental contaminants to innovating public health approaches in chemical management.

Dr. James Gomes, PhD is an Associate Expert with Risk Sciences International and an associate professor at the Interdisciplinary School of Health Sciences, University of Ottawa. Dr. Gomes is affiliated with the Institute of Population Health, Institute of Environment, and Center for Advanced Research in Environmental Genomics.

Dr. Andersen's illustrious 45-year career in toxicology and risk assessment includes key positions such as Chief Science Officer at The Hamner Institutes for Health Sciences and Professor of Environmental Health at Colorado State University. His significant contributions include developing biologically realistic models for toxic chemical and drug effects, notably in physiologically based pharmacokinetic (PBPK) modeling, advancing the field of chemical risk assessment. Dr. Andersen's prolific research output consists of over 500 papers and book chapters, earning him prestigious awards like the Lehman and Merit Awards from the US Society of Toxicology and the Mildred S. Christian Award from the Academy of Toxicological Sciences.